GUIAS HIPERTENSION ARTERIAL.indb - Scc

Revista Colombiana de Cardiología
Febrero 2007
3. The SOLVD Investigators. Effect of enalapril on mortality and development of
heart failure in asymptomatic patients with reduced left ventricular ejection
fractions and congestive heart failure. N Engl J Med 1992; 327: 685-691.
4. Packer M, Coats AJS, Fowler MB, et al; for the Carvedilol Prospective Randomized
Cumulative Survival Study Group. Effect of carvedilol on survival in severe
chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
5. The CONSENSUS Trail Study Group. Effect of enalapril on mortality in severe
congestive heart failure. Results of the Cooperative North Scandinavian Enalapril
Survival Study. N Engl J Med 1987; 316: 1429-1435.
6. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and
morbidity in patients with left ventricular dysfunction after myocardial infarction.
Results of the survival and ventricular enlargement trial. The SAVE Investigators.
N Engl J Med 1992; 327: 669-677.
7. Kober L, Torp-Pedersen C, Carlsen JE, et al; for the Trandolapril Cardiac Evaluation
(TRACE) Study Group. Effect on mortality by trandolapril after myocardial
infarction. N Engl J Med 1995; 333: 1670-1676.
8. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial
infarction in patients with left ventricular dysfunction: The CAPRICORN randomised
trial. Lancet 2001; 357: 1385-1390.
9. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker,
in patients with severe left ventricular dysfunction following myocardial infarction.
N Engl J Med 2003; 348: 1309-1321.
10. Kenneth D, Kjekshus J, and The OPTIMAAL Steering Committee. Effects of losartan
and captopril on mortality and morbidity in high-risk patients after acute myocardial
infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752-760.
11. Pfeffer MA, McMurray JJV, Velasquez E, et al. Valsartan, captopril, or both in
myocardial infarction complicated by heart failure, left ventricular dysfunction,
or both. N Engl J Med 2003; 349: 1893-1906.
12. Lopez B, Querejeta R, Gonzalez A, et al. Effects of loop diuretics on myocardial
fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol
2004; 43: 2028-2035.
13. Remme WJ, Swedberg K. Task Force for the diagnosis and treatment of chronic
heart failure. European Society of Cardiology. Guidelines for the diagnosis and
treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
14. ACC/AHA Guidelines for the evaluation and management of chronic heart failure
in the adult. Executive summary. J Am Coll Cardiol 2001; 38: 2101-2113.
15. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced
left ventricular ejection fractions and congestive heart failure. N Engl J Med
1991; 325: 293-302.
16. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker
valsartan in chronic heart failure (Valsartan Heart Failure Trial Investigator). N
Engl J Med 2001; 345: 1667-1675.
17. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high
doses of the angiotensin-converting enzyme inhibitor lisinopril on morbidity and mortality
in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-2318.
18. McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the
use of ACE inhibitors, beta blockers, aldosterone antagonists and angiotensin
receptor blockers in heart failure: putting guidelines into practice. Eur J Heart
Fail 2005; 7: 710-721.
19. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe
chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
20. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression
in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study
Group. Circulation 1996; 94: 2800-2806.
21. Australia-New Zealand Heart Failure Research Collaborative Group. Randomized,
placebo controlled trial of carvedilol in patients with congestive heart failure due
to ischaemic heart disease. Lancet 1997; 349: 375-380.
22. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol study
II (CIBIS II): A randomized trial. Lancet 1999; 353: 9-13.
23. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:
metoprolol CR/XL randomized intervention trial in congestive heart failure
(MERIT-HF). Lancet 1999; 353: 2001-2007.
Vol. 13 Suplemento 1
ISSN 0120-5633
271
24. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in
idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-1446.
25. CIBIS Investigators and Committees. A randomized trial of beta blockade in
heart failure. The Cardiac Insufficiency Bisoprolol study (CIBIS). Circulation
1994; 90: 1765-1773.
26. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol
and metoprolol on clinical outcomes in patients with chronic heart failure in the
Carvedilol Or Metoprolol European Trial (COMET): randomized trial. Lancet
2003; 362: 7-13.
27. Krum H, Hill J, Fruhwald F, et al. Tolerability of beta-blockers in elderly patients with
chronic heart failure: the COLA II study. Eur J Heart Fail 2006; 8: 302-307.
28. Willenheimer R, van Veldhuisen DJ, Silke B, et al; CIBIS III Investigators. Effect on
survival and hospitalization of initiating treatment for chronic heart failure with
bisoprolol followed by enalapril, as compared with the opposite sequence: results
of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation
200; 112: 2426-2435.
29. Komajda M, Lutiger B, Madeira H, et al. CARMEN investigators and co-ordinators.
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of
CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J
Heart Fail 2004; 6: 467-475.
30. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity
and mortality in patients with severe heart failure. The randomized aldactone
evaluation study. N Engl J Med 1999; 341: 709-717.
31. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with
chronic heart failure and reduced left ventricular systolic function intolerant to
angiotensin converting enzyme inhibitors: The CHARM-Alternative trial. Lancet
2003; 362: 772-776.
32. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril
on mortality in patients with symptomatic heart failure: randomized trial- The
Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
33. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker
valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
34. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients
with chronic heart failure and reduced left ventricular systolic function taking
angiotensin converting enzyme inhibitors: the CHARM Added trial. Lancet 2003;
362: 767-771.
35. Executive Council of The Heart Failure Society of America. HFSA Position
Statement: Implications of recent clinical trials for heart failure performance
measures. J Card Fail 2004; 10: 4-5.
36. Massie BM. 2003: the year in heart failure. J Card Fail 2004; 10: 1-3.
37. Packer M, O‘Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and
mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114.
38. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension
to congestive heart failure. JAMA 1996; 275: 1557-1562.
39. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy
and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol
1996; 27: 1214-1218.
40. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive
heart failure practice guideline. J Card Fail 2006; 12: 10-38.
41. Swedberg K, Cleland J, Dargie H, et al; Task force for the diagnosis and treatment
of chronic heart failure of the European Society of Cardiology. Guidelines for
the diagnosis and treatment of chronic heart failure: executive summary (update
2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure
of the European Society of Cardiology. Eur Heart J 2005; 1115-1140.
42. McMurray J, Swedberg K. Treatment of chronic heart failure: a comparison
between the major guidelines. Eur Heart J 2006; 27: 1773-1777.
43. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as
supplementary vasodilator therapy in patients with chronic heart failure treated
with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group
Circulation.1997; 96: 856-863.
44. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication
of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:
543-551.